Patients on Lilly's next-gen obesity drug lost 28% of body weight, company says

Eli Lilly said retatrutide helped obesity patients lose more than 28% of their weight over 1.5 years in a key trial, strengthening the case for regulatory approval. The result supports a potential launch next year and is a meaningful positive for Lilly’s obesity pipeline. The news is favorable for the stock, though the article does not indicate an approved product yet.

Analysis

Eli Lilly said retatrutide helped obesity patients lose more than 28% of their weight over 1.5 years in a key trial, strengthening the case for regulatory approval. The result supports a potential launch next year and is a meaningful positive for Lilly’s obesity pipeline. The news is favorable for the stock, though the article does not indicate an approved product yet.